Please note, as this is a prescription item, one of our doctors will review your profile and approve your order if appropriate. A prescription will only be issued in accordance to the prescribing guidelines, and for use that strictly complies to the doctor’s directions and dosage. This script will be forwarded to our dispensary team, and placed in our secure, internal records.
This peptide is a modified fragment of hGH which contains the portion of the molecule that is believed to be responsible for hGH’s anti-obesity effects. The peptide has been shown to increase fat burning without the increase in blood sugar and growth rate that has been seen with hGH itself. AOD 9604 has been deemed safe for chronic use by the FDA, receiving Human GRAS status in 2014. In addition to its utility as an anti-obesity peptide, AOD 9604 has been shown to have very favorable cartilage repair and regenerative properties, especially when paired with peptide BPC 157.
CJC-1295 and Mod GRF 1-29 are administered in micrograms (mcg) rather than milligrams (mg) – the unit of administration of other steroids and performance-enhancing drugs. It has also been found that a 100mcg dose is enough to fully saturate the receptors in the anterior pituitary. This is called the saturation dose. After a dose of 100mcg has been administered, the subsequent dosages will achieve only half the effect.
3. Since actual HGH shuts down the body's natural pituitary gland, when you stop injecting it, your body's own ability to produce Growth Hormone is hindered and you will suffer a rebound of negative side effects such as fat gain, muscle loss and loss of skin tone/elasticity. This means you may end up doing yourself more harm than good. Since GH releasing peptides only stimulate your body's own natural production, there is no rebound negative effects if you stop usage.

I have no direct personal reports on effect of the compound. There have been a few reports put out on the Internet, but I have no better ability to summarize such findings than anyone else and generally don’t go by that, except of course I do give credence when there’s a clear, large body of results. That’s not the case here, and what there is, is certainly not in the direction of this being the next wonder.


I'm new to the forum and there is some great information here that I need to do more reading on. I've been taking Ipam and ModGrf 1-29 for at least 2yrs now. The first thing I noticed is that I have good quality sleep. I have difficulty sleeping and staying asleep. I take these peps 20min before I go to bed and get a good deep sleep for at least most of the night. I take them before doing my morning cardio, after my workout (afternoon) and before I go to bed. I've read if you take it before your morning cardio it releases more FFA to burn during your session. After the workout to aid in recovery. Before bed to aid in a deeper sleep. It is important when you take them. Dont eat before morning cardio...no carbs/sugary drinks...3hrs should have passed before taking another shot and do not eat before 15-20min after taking the peps. The reason (I've read) to wait these times is to take them while your insulin levels are low. High Insulin levels will minimize the pulsation of the GH. The phrase I've read is to try to keep "insulin quiet" to maximize the pulse of GH. Ipam can work by itself but if taken with ModGrf 1-29 it will magnify the GH Pulse. ModGrf is useless by itself. I've read that there is a saturation dose, so more is not better. 200mcg for each should do the job. Since synthetic GH shuts down natural production, these peps stimulate the pituitary to pulse more natural GH. To get the maximum effect of syn GH, you would also take the shot at the same time discussed above. Once again, this is what I've read and the protocol that I've followed. The results arent like AAS (nothing is!) but it is a good way to feel better since I cant take TRT. (trying to have kids) I also travel with the peps bc I value the sleep that I get from it.

If your unaccompanied goal is huge loss, it’s regularly best to skulk the act with regard to of GHRP products (GHRP-6, GHRP-2 or Hexarelin) being they gave a pink slip stimulate feel a dearth of and/or am a dealer of strength cortisol, both of which boot be counterproductive to immense burning. Ipamorelin, on the other laborer makes a great addition for it has no marching to a different drummer side chattels personal and increases GH secretion ultimately more, providing the applied force for drastic reductions in fat.
AOD9604 is promoted heavily by various manufacturers as a substance that is able to burn fat and assist in the repair of muscle and cartilage. The fact that this product derives from, and claims to mimic the effects of a powerfully anabolic banned substance provides a psychological incentive to many potential users, as does the attention drawn by the AFL "peptides" scandal of early 2013 and the subsequent report by the Australian Crime Commission (1).
Prof. Gary Wittert, Adelaide-based Principal Investigator on the study, said: “As the world’s first drug with a metabolic mechanism of action AOD9604 could occupy a unique position among the options available to doctors for the management of obesity. It is pleasing that the invention and its development from the laboratory bench has been an all–Australian effort.”
The human growth hormone (hGH) is a 191-amino acid long, single-chain polypeptide secreted by the pituitary gland under the regulation of the hypothalamus. It regulates a variety of biological processes in various tissues. When binding to the hGH-receptor it activates one of various signaling cascades, depending on the tissue. In the liver hGH induces the secretion of Insulin-Like Growth Factor-1 (IGF-1). IGF-1 can stimulate growth in almost every tissue in the body, including skeletal muscle, cartilage, bone, liver, kidney, nerves etc. [1].
The expression of β3-AR RNA was assessed by RT by using radiolabeled primers and Southern blot analysis. Labeled bands were identified and semiquantitated by phosphorimaging. RT-PCR analysis demonstrated that ob/ob mice express lower amounts ofβ 3-AR RNA in their white (Fig. 3A) and brown (Fig. 3B) adipose tissues, compared with lean C57BL/6J mice, in agreement with others (14). Figure 3A shows the effect of saline, AOD9604, and hGH on β3-AR RNA expression in epididymal adipose tissue from both lean and obese mice, respectively. The level of β3-AR expression increased significantly in response to AOD9604 and hGH only in the obese mice, correlating with the significant decrease in epididymal adipose tissue weights seen in these mice. The same correlation was observed in brown adipose tissue, where increased expression of β3-AR was accompanied by a decrease in brown adipose tissue mass in both lean and obese mice (Fig. 3B).

Finally, the hexadecapeptide AOD9604 did not induce allergenic reactions when consumed over 24 weeks. Blood of patients was analyzed for the presence of anti-AOD9604 antibody formation at various times and at the end of the studies (latest time point after 24 weeks). In none of the performed studies, at no time, were anti-AOD9604 antibodies detected in serum collected from any subjects in any treatment group.
The peptide therapy protocols (Amino Acid Analogs) prescribed by TeleWellnessMD providers are also known as secretagogues (pronounced se-creta-gog), a substance that promotes secretion. These amino acid chains communicate with the body to produce or release growth hormone. Hence a secretagogue causes the body’s own natural processes to produce growth hormone. Secretagogues do not act as growth hormones but rather stimulate the pituitary gland to secrete your stored growth hormone. The subcutaneous injection route of growth hormone stimulation is a preferred route to help slow down age and environmental reductions in growth hormone levels.
AOD9604 is a peptide (a chain of amino acids) which was developed and patented by a company called Metabolic Pharmaceuticals in Australia in the late 1990s. AOD stands for "Anti Obesity Drug". This peptide has an amino acid sequence that mimics the lipolytic region of human growth hormone (the region of this hormone thought to be responsible for burning fat) and it has been promoted variously as a weight loss supplement, as an aid to muscle and cartilage repair, and a treatment for osteoarthritis by its manufacturers. It is also known as lipotropin and Tyr-hGH fragment, and is generally available these days as a transdermal cream or an injectable.
I have been using sermorelin (bioidentical growth hormone releasing hormone) for 2 months now to help heal a nasty right quad tendon rupture suffered the end of December. I’m 52 years old with 7% bodyfat and am a lifetime strength trainer and former high level bike racer. 2 months ago, in spite of months of religious rehab, I couldn’t do a single right leg bench stepup. Yesterday I was doing 20lb DB’s for repeated sets of 15. I get complete blood panels every 6 months, and my last labs in May showed my IGF-1 levels off the reference range low. I get my next bloods in a couple of weeks. I was initially afraid to try this hormone due to the cancer implications, and I didn’t need it to be lean and fit, but I was desperate and for my injury recovery, and it has made a significant difference. Plus, I believed supplementing the releasing hormone vs, IGF-1 limits the possibility of increasing the levels too much, as well as causing a negative feedback loop. By the way, I also tried TB-500 previous to the sermorelin, and it seemed to make some other achy joints in the gym go away, but didn’t seem to help the quad injury.
During the hydrolysis process, whole proteins are broken down into smaller peptide fragments. These can sometimes be as short as two or three amino acids in length (known as di- and tri-peptides). The benefits of hydrolysed protein have been outlined in detail elsewhere. In short, hydrolysed proteins are much faster absorbed than other forms of protein. It has been shown that hydrolysed whey protein can increase the time of recovery compared to whey protein isolate (WPI) (Buckley et al, 2010).

The known side effects of IGF-1 injections include jaw pain, facial and hand swelling and heart-rhythm disturbances, especially if doses of more than 100 micrograms (mcg) are injected. Exceeding 100mcg of IGF-1 can actually cause your heart to stop beating and blood pressure to drop dramatically. This is caused by an IGF-1-induced drop in blood phosphate levels, and in the bodybuilding community is often prevented by administering phosphate with the IGF-1.
One submission was received, which did not support the delegate's interim decision, as available data support that the fixed dose paracetamol/caffeine combination product provides clinically meaningful efficacy over paracetamol alone; has an excellent safety profile; a very low risk of nephrotoxicity, toxicity in overdose, misuse, abuse or illicit use; and a highly favourable risk/benefit profile.
There were no significant changes in IGF-1 values observed during 24 hours following any AOD9604 dose compared with placebo. No significant differences in glucose levels were observed following AOD9604 administration compared with placebo with the exception of one isolated time point (8% increase 12 hour post treatment in one subject receiving 54 mg AOD09604). There were no clinically significant observable trends in vital signs, physical examinations, abnormalities noted in the ECG measurements, or findings in the safety-related laboratory tests throughout the study.
Both AOD9604 and, to a greater extent, hGH increase body weight in lean mice, compared with saline-treated animals. This is in the absence of an increase in fat mass, which suggests an increase in lean body mass occurs with these compounds. This supports previous work with hGH in rodents and humans (17). Both compounds have also been previously shown to reduce body weight and adiposity in obese mice (11). The effects of hGH and AOD9604 occur without significant changes to caloric intake. It has been reported that hGH increases, reduces, or does not change food intake in which the differences are attributed to variations in hGH preparations, concentrations, and animals used between different laboratories.

If muscle gain is not what you’re looking to gain, then the best place to start is by getting your hands on some CJC-DAC and administer at 2-5mg per week. CJC-1295 with or without DAC is suitable. An equally effective alternative is GW501516. Peptide Clinics Australia recommend Oxytocin for weight loss highly and they’ve had amazing results from patients that have been prescribed this.

Both AOD9604 and, to a greater extent, hGH increase body weight in lean mice, compared with saline-treated animals. This is in the absence of an increase in fat mass, which suggests an increase in lean body mass occurs with these compounds. This supports previous work with hGH in rodents and humans (17). Both compounds have also been previously shown to reduce body weight and adiposity in obese mice (11). The effects of hGH and AOD9604 occur without significant changes to caloric intake. It has been reported that hGH increases, reduces, or does not change food intake in which the differences are attributed to variations in hGH preparations, concentrations, and animals used between different laboratories.
The effects of hGH and AOD9604 on fat metabolism may be mediated by an alteration in the expression of a lipolytic/antilipogenic gene. Theβ 3-AR is a major lipolytic receptor identified in rodent fat cells (18) that mediates its effects through G protein coupling to adenylate cyclase, generation of cAMP, and stimulation of PKA (19). This enzyme then phosphorylates proteins in the lipolytic cascade, including hormone-sensitive lipase (20). In BAT, the β3-AR stimulates uncoupling of the electron transport chain, enhancing the ability of mitochondria to generate heat in preference to ATP through the dissipation of the electron gradient (21). Mice that lack this receptor have lower rates of resting energy expenditure (0.0041 vs. 0.0047 kcal/min, P < 0.02) and lower rates of fat oxidation (0.00019 vs. 0.00030 g/min, P < 0.02) than control mice (data not shown).

The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the Committee included: a) the risks and benefits of the use of a substance; b) the purposes for which a substance is to be used and the extent of use of a substance; c) the toxicity of a substance; d) the dosage, formulation, labelling, packaging and presentation of a substance; and f) any other matters that the Secretary considers necessary to protect public health.
As a general rule, regardless of your goal, if you are just looking to take one product, with the least amount of fuss and injections as possible, then it should be CJC-1295 DAC at 2mg (1 vial) per week. Due to its long half-life it causes your overall level of GH (Growth Hormone) to rise, and you will therefore see some improvements in things which go along with having higher levels of GH and IGF-1 such as improved body shape, sleep, skin and general wellbeing (although it can make you tired for the first 1-2 weeks while the body adjusts). Your dosage can be taken as just one injection per week (note that you may notice a head rush/flushing for 15-20 minutes after your injection due to the release of GABA in the body, a sign the product is working).
Phenylephrine is readily eliminated by sulphate conjugation in the intestinal wall, and oxidative deamination by monoamine oxidative glucuronidation in the liver. Monoamine oxidase (MAO) inhibitors can enhance the limited potential of phenylephrine for cardiac and pressor effects, by reducing metabolism. As a largely specific alpha adrenergic drug, with very weak beta agonism, there is little direct cardiac effect. However, in higher doses, there can be increases in both systolic and diastolic blood pressure and a reflex bradycardia. As an adrenergic agonist there is the potential to interact with other sympathomimetic drugs. In overdose phenylephrine can cause hypertension, headaches seizures tachycardia, and vomiting. There has been no evidence from carcinogenicity studies in rodents of any enhanced cancer risk over prolonged exposure.
AOD9604 is a new synthetic peptide fragment that comprises a modified 15 amino acid region of GH with a tyrosine component to help stabilize the molecule. Similar to GH, AOD9604 aids weight reduction in rodent models of obesity and was originally developed for the treatment of obesity in humans [11]. Additionally, it does not stimulate the production of IGF-1 [10], has positive effects on the differentiation of adipose mesenchymal stem cells into bone, and was found to promote proteoglycan and collagen production in isolated bovine chondrocytes in an in vitro study by Metabolic Pharmaceuticals (patent applied [WO2013082667]). Its positive effects include promoting the repair of bone and cartilage in cases of OA.
Perhaps. As Dr Larkins weighs in: "It's a different kind of chemical and physiological manipulation that goes way beyond what I'd call conventional hormone therapy. It's the next stage of technology that's come along to try and help people enjoy quality of life." A stage with an effect apparently significant enough to risk a professional athletic career for.
×